Transduction of human CD34+ repopulating cells with a self-inactivating lentiviral vector for SCID-X1 produced at clinical scale by a stable cell line

Human Gene Therapy Methods

Volumn 23, Issue 5, 2012, Pages 297-308

  Greene, Michael R ^a   Lockey, Timothy ^a   Mehta, Perdeep K ^a   Kim, Yoon Sang ^a   Eldridge, Paul W ^a   Gray, John T ^a   Sorrentino, Brian P ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; LENTIVIRUS VECTOR; RETROVIRUS VECTOR; SELF INACTIVATING LENTIVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL ASSAY; CELL POPULATION; CLONAL VARIATION; COLONY FORMING UNIT; CONTROLLED STUDY; COPY NUMBER VARIATION; ENGRAFTMENT; FEMALE; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN GENOME; IN VITRO STUDY; IN VIVO STUDY; LYMPHOID CELL LINE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STEM CELL GENE THERAPY; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS GENOME; X LINKED SEVERE COMBINED IMMUNODEFICIENCY; XENOTRANSPLANTATION;

ANIMALS; ANTIGENS, CD34; BIOREACTORS; CELL LINE; DISEASE MODELS, ANIMAL; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; LENTIVIRUS; LYMPHOCYTES; MICE; MYELOID CELLS; TRANSDUCTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS; X-LINKED COMBINED IMMUNODEFICIENCY DISEASES;

EID: 84878746232     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2012.150     Document Type: Article

References (50)

1. Bhatia, M., Wang, J.C., Kapp, U., et al. (1997). Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 94, 5320-5325. (Pubitemid 27214781)
2. Broussau, S., Jabbour, N., Lachapelle, G., et al. (2008). Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture. Mol. Ther. 16, 500-507. (Pubitemid 351314989)
3. Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C.C., et al. (2009) Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818-23.
4. Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C.C., et al. (2012). Lentiviral hematopoietic cell gene therapy for X-linked adrenoleukodystrophy. Methods Enzymol. 507, 187-198.
5. Cavazzana-Calvo, M., Payen, E., Negre, O., et al. (2010). Transfusion independence and HMGA2 activation after gene therapy of human b-thalassaemia. Nature 467, 318-322.
6. Chinen, J., Davis J., De Ravin, S.S., Hay, B.N., et al. (2007). Gene therapy improves immune function in preadolescents with X-linked severe combined immunodeficiency. Blood 110, 67-73. (Pubitemid 47026820)
7. Emery, D.W. (2011). The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors. Hum. Gene Ther. 22, 761-74.
8. Evans-Galea, M.V., Wielgosz, M.M., Hanawa, H., et al. (2007). Suppression of clonal dominance in cultured human lymphoid cells by addition of the cHS4 insulator to a lentiviral vector. Mol. Ther. 15, 801-809. (Pubitemid 46432001)
9. Fischer, A., Hacein-Bey-Abina, S., and Cavazzana-Calvo, M. (2011). Gene therapy for primary adaptive immune deficiencies. J Allergy Clin Immunol 127, 1356-1359.
10. Gaspar, H.B., Parsley, K.L., Howe, S., et al. (2004). Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364, 2181-2187. (Pubitemid 40018447)
11. Gaspar, H.B., Cooray, S., Gilmour, K.C., et al. (2011). Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci. Transl. Med. 3, 97ra79.
12. GE Healthcare (2008), WAVE Bioreactor 2/10 Operator Manual 87-4500-23 AH 11.
13. Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415-419. (Pubitemid 37296260)
14. Hacein-Bey-Abina, S., Garrigue, A., Wang, G.P., et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118, 3132-3142.
15. Hacein-Bey-Abina, S., Hauer, J., Lim, et al. (2010). Efficacy of gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 363, 355-364.
16. Hematti, P., Hong, B.K., Ferguson, C., et al. (2004). Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol 2, e423.
17. Howe, S.J., Mansour, M.R., Schwarzwaelder, K., et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118, 3143-3150.
18. Ikeda, Y., Takeuchi, Y., Martin, F., et al. (2003). Continuous hightiter HIV-1 vector production. Nat Biotechnol 21, 569-572. (Pubitemid 36532025)
19. Ishikawa, F., Yasukawa, M., Lyons, B., et al. (2005). Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood 106, 1565-1573. (Pubitemid 41208567)
20. Ito, M., Kobayashi, K., and Nakahata, T. (2008). NOD/Shi-scid IL2rgamma(null) (NOG) mice more appropriate for humanized mouse models. Curr. Top Microbiol. Immunol. 324, 53-76.
21. Kim, Y.J., Kim, Y.S., Larochelle, A., et al. (2009). Sustained highlevel polyclonal hematopoietic marking and transgene expression 4 years after autologous transplantation of rhesus macaques with SIV lentiviral vector-transduced CD34 + cells. Blood 113, 5434-43.
22. Kim, Y.S., Wielgosz, M.M., Hargrove, P., et al. (2010). Transduction of human primitive repopulating hematopoietic cells with lentiviral vectors pseudotyped with various envelope proteins. Mol. Ther. 18, 1310-1317.
23. Klages, N., Zufferey, R., and Trono, D. (2000). A stable system for the high-titer production of multiply attenuated lentiviral vectors. Mol Ther 2, 170-176.
24. Larochelle, A., Vormoor, J., Hanenberg, H., et al. (1996). Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. Nat Med 2(12), 1329-37.
25. Lepus, C.M., Gibson, T.F., Gerber, S.A., et al. (2009). Comparison of human fetal liver, umbilical cord blood, and adult blood hematopoietic stem cell engraftment in NOD-scid/gammac-/-, Balb/c-Rag1-/-gammac-/-, and C.B-17-scid/bg immunodeficient mice. Hum. Immunol. 70, 790-802.
26. McDermott, S.P., Eppert, K., Lechman, E.R., et al. (2010). Comparison of human cord blood engraftment between immunocompromised mouse strains. Blood 116, 193-200.
27. Merten, O.W., Charrier, S., Laroudie, N., et al. (2011). Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum. Gene Ther. 22, 343-56.
28. Mitchell, R.S., Beitzel, B.F., Schroder, A.R., et al. (2004). Retroviral DNA integration, ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2, E234.
29. Montini, E., Cesana, D., Schmidt, M., et al. (2006). Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 24, 687-96. (Pubitemid 43882120)
30. Montini, E., Cesana, D., Schmidt, M., et al. (2009). The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J. Clin. Invest. 119, 964-975.
31. Ni, Y., Sun, S., Oparaocha, I., et al. (2005). Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector. J. Gene Med. 7, 818-834. (Pubitemid 40872867)
32. Ryu, B.Y., Evans-Galea, M.V., Gray, J.T., et al. (2008). An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation. Blood 111, 1866-1875. (Pubitemid 351451495)
33. Scaramuzza, S., Biasco, L., Ripamonti, A., et al. (2012). Preclinical Safety and Efficacy of Human CD34( + ) Cells Transduced With Lentiviral Vector for the Treatment of Wiskott-Aldrich Syndrome. Mol. Ther. [Epub ahead of print]; DOI: 10.1038/mt.2012.23
34. Schmidt, M., Schwarzwaelder, K., Bartholomae, C., et al. (2007). High-resolution insertion-site analysis by linear amplificationmediated PCR (LAM-PCR). Nat. Methods 4, 1051-1057. (Pubitemid 350201778)
35. Schrö der, A.R., Shinn, P., Chen, H., et al. (2002). HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110, 521-529. (Pubitemid 35232295)
36. Schweizer, M., and Merten, O.W. (2010). Large-scale production means for the manufacturing of lentiviral vectors. Curr. Gene Ther. 10, 474-486.
37. Sellers, S., Gomes, T.J., Larochelle, A., et al. (2010). Ex vivo expansion of retrovirally transduced primate CD34 + cells results in overrepresentation of clones with MDS1/EVI1 insertion sites in the myeloid lineage after transplantation. Mol. Ther. 18, 1633-1639.
38. Shou, Y., Ma, Z., Lu, T., and Sorrentino, B.P. (2006). Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc. Natl. Acad. Sci. U.S.A. 103, 11730-11735. (Pubitemid 44182519)
39. Stein, S., Ott, M.G., Schultze-Strasser, S., et al. (2010). Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 16(2), 198-204.
40. Thrasher, A.J., Hacein-Bey-Abina, S., Gaspar, H.B., et al. (2005). Failure of SCID-X1 gene therapy in older patients. Blood 105, 4255-4257. (Pubitemid 40720770)
41. Throm, R.E., Ouma, A.A., Zhou, S., et al. (2009). Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood 113, 5104-5110.
42. Uchida, N., Hsieh, M.M., Hayakawa, J., et al. (2011). Optimal conditions for lentiviral transduction of engrafting human CD34 + cells. Gene Ther 18, 1078-1086.
43. Wang, J.C., Doedens, M., and Dick, J.E. (1997). Primitive human hematopoietic cells are enriched in cord blood compared with adult bone marrow or mobilized peripheral blood as measured by the quantitative in vivo SCID-repopulating cell assay. Blood 89, 3919-3924. (Pubitemid 27220934)
44. Woods, N.B., Muessig, A., Schmidt, M., et al. (2003). Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis. Blood 101, 1284-1289. (Pubitemid 36182497)
45. Wu, X., Li, Y., Crise, B., and Burgess, S.M. (2003) Transcription start regions in the human genome are favored targets for MLV integration. Science 300, 1749-1751. (Pubitemid 36712571)
46. Xu, K., Ma, H., McCown, T.J., et al. (2001). Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol. Ther. 3, 97-104. (Pubitemid 32509810)
47. Yahata, T., Yumino, S., Seng, Y., et al. (2006). Clonal analysis of thymus-repopulating cells presents direct evidence for selfrenewal division of human hematopoietic stem cells. Blood 108, 2446-2454. (Pubitemid 44497532)
48. Zhou, S., Mody, D., DeRavin, S.S., et al. (2010). A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells. Blood 116, 900-908.
49. Zufferey, R., Dull, T., Mandel, R.J., et al. (1998). Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72, 9873-9880. (Pubitemid 28520853)
50. Zychlinski, D., Schambach, A., Modlich, U., et al. (2008). Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol. Ther. 16, 718-725. (Pubitemid 351426173)